Ms Jelena Pavlovic

Ms Jelena Pavlovic

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

Jelena Pavlovic is an epidemiologist with strong affinity for public health, originally trained as a medical doctor at the Faculty of Medicine in Belgrade (Serbia). Epidemiological studies in the field of preventive cardiology are main focus of her PhD thesis, that she is carrying out at the Department of Epidemiology at Erasmus Medical Center in Rotterdam (The Netherlands). She also worked as a field epidemiologist for Medecines Sans Frontières.

Presentations

Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study

Event: ESC Congress 2020

Topic: Scores

Session: Non-statin Treatment of Dyslipidemia

Access

Recommendations and associated levels of evidence for statin use in primary prevention of cardiovascular disease: a comparison at population level of the ESC, ACC/AHA, USPSTF, and CCS Guidelines

Event: ESC Congress 2020

Topic: Epidemiology

Session: Risk Factors and Prevention ePosters

Access

Clinical implications of low-to-intermediate trials for primary prevention of atherosclerotic CVD and risk stratification with N-terminal pro-B-type natriuretic peptide in the Rotterdam Study

Event: EuroPrevent 2017

Topic: Epidemiology, lipids

Session: Epidemiology/ Public health_Part 1

Access

Translation of evidence from 11 randomized clinical trials on statin use in primary prevention of cardiovascular disease into ESC 2016 and ACC/AHA 2013 guidelines: results from the Rotterdam Study

Event: EuroPrevent 2017

Topic: Epidemiology, lipids

Session: Rapid Fire Abstract session II

Access

Ms Jelena Pavlovic

Biography

Contributor content

Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study

Recommendations and associated levels of evidence for statin use in primary prevention of cardiovascular disease: a comparison at population level of the ESC, ACC/AHA, USPSTF, and CCS Guidelines

Clinical implications of low-to-intermediate trials for primary prevention of atherosclerotic CVD and risk stratification with N-terminal pro-B-type natriuretic peptide in the Rotterdam Study

Translation of evidence from 11 randomized clinical trials on statin use in primary prevention of cardiovascular disease into ESC 2016 and ACC/AHA 2013 guidelines: results from the Rotterdam Study

ESC 365 is supported by